Abstract
Dendritic nanoparticles have been developed with auspicious properties like high loading capacity for guest molecules, low polydispersity and tunable end groups. Demonstrating increased cellular uptake and bypassed efflux transporters, dendritic nanoparticles may offer new treatment options for therapy-resistant diseases. New core-shell architectures address the drawbacks of initial approaches. Especially tecto-dendrimers, bearing low-radii dendrimers on the surface of a bigger dendrimer, as well as the core-multishell architectures with an alkyl inner shell and a monomethylpoly(ethylene glycol) outer shell, gained interest for dermatotherapy. Moreover, the integration of e.g. pH labile groups into dendritic nanoparticles may offer triggered drug release. However, before declaring dendritic nanoparticles as an ultimate drug delivery system for skin penetration, dendritic nanoparticles need to prove their efficacy and safety in non-clinical, and subsequently in clinical studies.
Here, we review major characteristics of human skin, and thus target structures for topical drug delivery systems. Focusing on the use as in vitro test system, we summarize the features of reconstructed human skin. Since drug delivery systems are intended to be applied to diseased skin, we additionally review latest insights into disease-related changes in the highly prevalent skin diseases such as atopic dermatitis, and cutaneous squamous cell carcinoma, as well as in their respective human cell-based skin disease models.
We will conclude with the proposal of an integrated test strategy to promote the introduction of dendritic nanoparticles into medicinal products.
Keywords: Atopic dermatitis, dendrimers, drug delivery systems, non-melanoma skin cancer, reconstructed human skin, skin penetration, tight junctions.
Current Pharmaceutical Design
Title:Dendritic Nanoparticles for Cutaneous Drug Delivery - Testing in Human Skin and Reconstructed Human Skin
Volume: 21 Issue: 20
Author(s): Christian Zoschke, Priscila Schilrreff, Eder L. Romero, Johanna M. Brandner and Monika Schafer- Korting
Affiliation:
Keywords: Atopic dermatitis, dendrimers, drug delivery systems, non-melanoma skin cancer, reconstructed human skin, skin penetration, tight junctions.
Abstract: Dendritic nanoparticles have been developed with auspicious properties like high loading capacity for guest molecules, low polydispersity and tunable end groups. Demonstrating increased cellular uptake and bypassed efflux transporters, dendritic nanoparticles may offer new treatment options for therapy-resistant diseases. New core-shell architectures address the drawbacks of initial approaches. Especially tecto-dendrimers, bearing low-radii dendrimers on the surface of a bigger dendrimer, as well as the core-multishell architectures with an alkyl inner shell and a monomethylpoly(ethylene glycol) outer shell, gained interest for dermatotherapy. Moreover, the integration of e.g. pH labile groups into dendritic nanoparticles may offer triggered drug release. However, before declaring dendritic nanoparticles as an ultimate drug delivery system for skin penetration, dendritic nanoparticles need to prove their efficacy and safety in non-clinical, and subsequently in clinical studies.
Here, we review major characteristics of human skin, and thus target structures for topical drug delivery systems. Focusing on the use as in vitro test system, we summarize the features of reconstructed human skin. Since drug delivery systems are intended to be applied to diseased skin, we additionally review latest insights into disease-related changes in the highly prevalent skin diseases such as atopic dermatitis, and cutaneous squamous cell carcinoma, as well as in their respective human cell-based skin disease models.
We will conclude with the proposal of an integrated test strategy to promote the introduction of dendritic nanoparticles into medicinal products.
Export Options
About this article
Cite this article as:
Zoschke Christian, Schilrreff Priscila, Romero L. Eder, Brandner M. Johanna and Schafer- Korting Monika, Dendritic Nanoparticles for Cutaneous Drug Delivery - Testing in Human Skin and Reconstructed Human Skin, Current Pharmaceutical Design 2015; 21 (20) . https://dx.doi.org/10.2174/1381612821666150428142515
DOI https://dx.doi.org/10.2174/1381612821666150428142515 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
GRP78 Influences Chemoresistance and Prognosis in Cancer
Current Drug Targets Chemoradiation for Oropharyngeal Carcinoma for Organ Preservation
Current Cancer Therapy Reviews The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases
Anti-Cancer Agents in Medicinal Chemistry The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Heterocyclic Curcumin Derivatives of Pharmacological Interest: Recent Progress
Current Topics in Medicinal Chemistry TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis and Single-Crystal X-Ray Diffraction Studies of an Arylidenethiosemicarbazone and Hydrazonyl-phenylthiazole
Letters in Organic Chemistry Nicotine Replacement Therapy During Pregnancy and Lactation Induce Structural and Functional Changes in the Lungs of the Progeny
Current Women`s Health Reviews Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020)
Current Medicinal Chemistry Using Insights into Pim1 Structure to Design New Anticancer Drugs
Current Pharmaceutical Design Methodological Issues of Clinical Research with EGFR Inhibitors
Current Cancer Therapy Reviews The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets FHIT and p53 Status and Response to Platinum-Based Treatment in Advanced Non-Small Cell Lung Cancer
Current Cancer Drug Targets ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Molecular and Thermodynamic Studies on DNA Triplex Formed in the Promoter Region of HMGB1 Gene as a Selective Target for Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology